VAXCELL-BIO THERAPEUTICS CO., LTD. Vaxcell-Bio Therapeutics Co., Ltd. Stock
Equities
A323990
KR7323990002
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17,220 KRW | -4.12% |
|
-16.20% | -23.30% |
| 2023 | Vaxcell-Bio Therapeutics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 | CI |
| 2021 | Vaxcell-Bio Therapeutics Co., Ltd.(KOSDAQ:A323990) added to S&P Global BMI Index | CI |
| Sales 2022 | - | Sales 2023 | 13.72 19K | Capitalization | 516B 714,778B |
|---|---|---|---|---|---|
| Net income 2022 | -6.82B -9,451B | Net income 2023 | -10.27B -14,226B | EV / Sales 2022 | - |
| Net cash position 2022 | 20.29B 28,091B | Net cash position 2023 | 49.69B 68,799B | EV / Sales 2023 | 33,994,130,725 x |
| P/E ratio 2022 |
-63.5
x | P/E ratio 2023 |
-42.9
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 75.92% |
More Fundamentals
* Assessed data
More news
| 1 day | -4.12% | ||
| 1 week | -16.20% | ||
| 1 month | +5.06% | ||
| 3 months | -10.31% | ||
| 6 months | -5.44% | ||
| Current year | -23.30% |
1 week
17 220.00
21 300.00
1 month
15 060.0025 200.00
Current year
14 350.0025 200.00
1 year
14 350.0047 416.67
3 years
14 350.0085 583.33
5 years
8 520.83249 750.00
10 years
8 520.83249 750.00
| Managers | Title | Age | Since |
|---|---|---|---|
Joon-Haeng Lee
CEO | Chief Executive Officer | 64 | - |
Jae-Jung Lee
CEO | Chief Executive Officer | 60 | 10-02-17 |
Taek-Gun Oh
AUD | Comptroller/Controller/Auditor | 48 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sung-Chang Jung
BRD | Director/Board Member | 67 | - |
Jae-Jung Lee
CEO | Chief Executive Officer | 60 | 10-02-17 |
Joon-Haeng Lee
CEO | Chief Executive Officer | 64 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 4 M€ | -4.41% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 17,220 | -4.12% | 971,964 |
| 24-05-30 | 17,960 | -2.76% | 779,868 |
| 24-05-29 | 18,470 | -7.56% | 3,903,943 |
| 24-05-28 | 19,980 | -0.84% | 1,290,258 |
| 24-05-27 | 20,150 | -1.95% | 794,288 |
End-of-day quote Korea S.E., May 30, 2024
More quotes
Vaxcell-Bio Therapeutics is a Korea-based company mainly engaged in the research and development of anti-angiogenic immunotherapy drugs. The Company's pipeline consists of the Vax-NK natural killer cell anti-cancer immunotherapy platforms, the Vax-DC dendritic cell anti-cancer immunotherapy platforms, and the Vax-CAR series next-generation advanced anti-cancer immunotherapy platforms. In addition, the Company manufactures and sells cytokine-based boxleukin-15, an anticancer immunotherapy exclusively for dogs. The Company sells its products in domestic and overseas markets.
Calendar
2024-08-12
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -23.30% | 286M | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- A323990 Stock
